 产品搜索 |
| 产品类别 |
| 推荐产品 |
 叔丁基二甲基氯硅烷 |
| 2-氯-4,6-二甲基吡啶 |
| 2-溴-4,6-二甲基吡啶 |
| 6-氯苯并三氮唑-1,1,3,3- |
| 1,3-二苯基异苯并呋喃 |
| 培哚普利 |
| 9-(4-乙酰氧基-3-乙酰氧 |
| 嘧啶-5-硼酸 |
| 2-氯-3-硝基-4-甲基吡啶 |
| 7-氮杂吲哚 |
| 4-氮杂吲哚 |
| 5-氮杂吲哚 |
| 6-氮杂吲哚 |
| 7-azaoxindole |
| 6-azaoxindole |
| 4-叔丁基苯硼酸 |
| D-氨基半乳糖盐酸盐 |
| N-乙酰基-D-氨基半乳糖 |
| 溴代葡萄糖苷 |
| 利培酮 |
| N-三氟乙酰基-L-赖氨酸 |
| N2-(1-乙氧羰基-3-苯丙基 |
| N2-[1-(S)-乙氧羰基-3-苯 |
| 3-氨基甲酰基苯硼酸 |
| 2,4-二氯-6-甲基嘧啶 |
| N-(4-氨基丁基)-N-乙基异 |
| AOP |
| BOP |
| 4,4-二甲氧基三苯甲基 |
| 2-氯-1-甲基吡啶碘盐 |
| HOTT |
| TSTU |
| 1-(4-甲磺基)-3-硝基-1,2,4 |
| TPTU |
| 2,4,6-三异丙基苯磺酰氯 |
| TOTU |
| TOTT |
| TNTU |
| TFFH |
| TDBTU |
| TCTU |
| TCFH |
| TBTU |
| TATU |
| N-Hydroxysulfosuccinimide sodi |
| 8-喹啉磺酰氯 |
| PyCloP |
| PYCLU |
| PyBroP |
| PyBOP |
|
| 产品展示 |
| 产品编号 |
产品名称 |
CAS No. |
含量 |
| W61892 | 3-(chloromethyl)-1-[1-(propan-2-yl)-1H-pyrazol-4-yl]pyridazin-4(1H)-one | 1314389-49-5 | 95% |
| W61893 | tert-butyl 2-[(1-methyl-1H-pyrazol-4-yl)diazenyl]-3-oxobutanoate | 1314388-86-7 | 95% |
| W61894 | 4-oxo-1-[1-(propan-2-yl)-1H-pyrazol-4-yl]-1,4-dihydropyridazine-3-carboxylic acid | 1314389-60-0 | 95% |
| W61895 | 3-(chloromethyl)-1-(1-isobutyl-1H-pyrazol-4-yl)pyridazin-4(1H)-one | 1314389-67-7 | 95% |
| W61896 | 5-[3-(hydroxymethyl)-4-oxopyridazin-1(4H)-yl]pyridine-3-carbonitrile | 1314389-44-0 | 95% |
| W61897 | 3-(chloromethyl)-1-(2,6-dichloropyridin-4-yl)pyridazin-4(1H)-one | 1314389-15-5 | 95% |
| W61898 | tert-butyl 4-oxo-1-(1H-pyrazol-4-yl)-1,4-dihydropyridazine-3-carboxylate | 1314389-53-1 | 95% |
| W61899 | 1-{[2-(3-chlorophenyl)pyrimidin-5-yl]oxy}-2-methylpropan-2-ol | 1314391-68-8 | 95% |
| W61900 | tert-butyl 1-(1-methyl-1H-pyrazol-4-yl)-4-oxo-1,4-dihydropyrazine-3-carboxylate | 1314388-87-8 | 95% |
| W61901 | methyl {4-[3-(chloromethyl)-4-oxopyridazin-1(4H)-yl]-1H-pyrazol-1-yl}acetate | 1314389-65-5 | 95% |
| W61902 | tert-butyl 4-oxo-1-[1-(propan-2-yl)-1H-pyrazol-4-yl]-1,4-dihydropyridazine-3-carboxylate | 1314389-59-7 | 95% |
| W61903 | methyl 3-{4-[3-(chloromethyl)-4-oxopyridazin-1(4H)-yl]-1H-pyrazol-1-yl}propanoate | 1314389-64-4 | 95% |
| W61904 | 5-methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-thiazole | 1314389-88-2 | 95% |
| W61905 | tert-butyl 4-(2-chloropyrimidin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate | 1314391-98-4 | 95% |
| W61906 | ethyl [3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate | 1314397-95-9 | 95% |
| W61907 | 2-methyl-5-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3,4-thidiazole | 1314390-88-9 | 95% |
| W61908 | methyl 4-{4-[3-(chloromethyl)-4-oxopyridazin-1(4H)-yl]-1H-pyrazol-1-yl}butanoate | 1314389-62-2 | 95% |
| W61909 | 5-methoxy-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine | 1314389-90-6 | 95% |
| W61910 | 3-(3-chlorobenzyl)-1-(1-ethyl-1H-pyrazol-4-yl)pyridazin-4-(1H)-one | 1314392-57-8 | 95% |
| W61911 | 3-(chloromethyl)-1-[1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]pyridazin-4(1H)-one | 1314389-66-6 | 95% |
| W61912 | 3-(imidazol[1,2-a]pyridin-6-ylmethyl)-1-(1-methyl-1H-pyrazol-4-yl)pyridazin-4(1H)-one | 1314381-03-7 | 95% |
| W61913 | 3-{[1-(1-methyl-1H-pyrazol-4-yl)-4-oxo-1,4-dihydropyridazin-3-yl]methyl}benzonitrile | 1314392-60-3 | 95% |
| W61914 | 1-(1-methyl-1H-pyrazol-4-yl)-3-(3-nitrophenyl)pyridazin-4-(1H)-one | 1314392-65-8 | 95% |
| W61915 | 3-(chloromethyl)-1-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-4-yl]pyridazin-4(1H)-one | 1314389-70-2 | 95% |
| W61916 | 1-propyl-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-1,2,4-triazole | 1314390-64-1 | 95% |
| W61917 | 1-(1-methyl-1H-pyrazol-4-yl)-3-[3-(1H-pyrazol-1-yl)benzyl]pyridazin-4(1H)-one | 1314380-78-3 | 95% |
| W61918 | 1-{1-[2-(benzyloxy)ethyl]-1H-pyrazol-4-yl}-3-(chloromethyl)pyridazin-4(1H)-one | 1314389-76-8 | 95% |
| W61919 | 1-(2-methoxyethyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-1,2,4-triazole | 1314390-70-9 | 95% |
| W61920 | 5-ethoxy-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrimidine | 1314390-96-9 | 95% |
| W61921 | 3-propoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline | 1314390-48-1 | 95% |
|
|
|
|
